Malta

Reimbursed Care Access

Malta follows EU/UN psychotropic scheduling for classic psychedelics (psilocybin, MDMA, DMT, mescaline etc.), meaning they are criminally controlled and only available for authorised research or exceptional clinical/regulatory pathways. Esketamine (Spravato) is authorised across the EU and therefore may be placed on the Maltese market, but routine public reimbursement and widespread public‑sector provision for psychedelic therapies (including ketamine infusions for TRD) remain limited or handled on a case‑by‑case / private‑clinic basis.